Fostamatinib Trial for Lung Transplant Patients with Donor-Specific Antibodies
A trial is underway to evaluate the safety and tolerability of fostamatinib in lung transplant patients with donor-specific antibodies.
Therapeutic Area
Therapeutic area intelligence for Transplant Rejection with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.